Prognostic value of the combination of serum l-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia

Leukemia and Lymphoma

Volumn 57, Issue 9, 2016, Pages 2208-2211

  Hara, Takeshi ^a   Matsumoto, Takuro ^a   Shibata, Yuhei ^a   Nakamura, Nobuhiko ^a   Nakamura, Hiroshi ^a   Ninomiya, Soranobu ^a   Kitagawa, Junichi ^a   Nannya, Yasuhito ^a   Shimizu, Masahito ^a   Ito, Hiroyasu ^a   Saito, Kuniaki ^b   Tsurumi, Hisashi ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CD135 ANTIGEN; CYTARABINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; RETINOIC ACID; MESSENGER RNA; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINO ACID BLOOD LEVEL; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; FEMALE; GENE EXPRESSION; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INDUCTION CHEMOTHERAPY; KARYOTYPE; LETTER; LEUKEMIA REMISSION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ACUTE MYELOID LEUKEMIA; AGED; BLOOD; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84954221738     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1128541     Document Type: Letter

References (15)

1. O.Takikawa Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun. 2005;338:12–19.
2. A.Huang, D.Fuchs, B.Widner, et al. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer. 2002;86:1691–1696.
3. R.Mabuchi, T.Hara, T.Matsumoto, et al. High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. Leuk Lymphoma. 2015. [Epub ahead of print]. DOI: 10.3109/10428194.2015.1041388.
4. K.Fukuno, T.Hara, H.Tsurumi, et al. Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. Leuk Lymphoma. 2015;56:1398–1405.
5. T.Yoshikawa, T.Hara, H.Tsurumi, et al. Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol. 2010;84:304–309.
6. S.Ninomiya, T.Hara, H.Tsurumi, et al. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol. 2011;90:409–416.
7. S.Ninomiya, T.Hara, H.Tsurumi, et al. Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53:1143–1145.
8. D.A.Arber, R.D.Brunning, A.Orazi, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: S.Swerdlow, E.Campo, N.L.Harris, editors. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Geneva: World Health Organization; 2008. p. 124–126.
9. J.M.Bennett, D.Catovsky, M.T.G.Daniel, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103:620–625.
10. D.Grimwade, H.Walker, F.Oliver, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–2333.
11. M.Hoshi, K.Saito, A.Hara, et al. The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol. 2010;185:3305–3312.
12. Y.Miyazaki, K.Kuriyama, S.Miyawaki, et al. Japan Adult Leukaemia Study Group. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. Br J Haematol. 2003;120:56–62.
13. H.Tsurumi, N.Kanemura, T.Hara, et al. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol. 2007;133:547–553.
14. H.Kiyoi, T.Naoe, Y.Nakano, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074–3080.
15. N.Nakamura, T.Hara, M.Shimizu, et al. Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice. Int J Hematol. 2015;102:327–334.